Success Metrics

Clinical Success Rate
78.6%

Based on 11 completed trials

Completion Rate
79%(11/14)
Active Trials
36(31%)
Results Posted
0%(0 trials)
Terminated
3(3%)

Phase Distribution

Ph phase_2
71
61%
Ph phase_3
8
7%
Ph phase_1
30
26%
Ph not_applicable
5
4%

Phase Distribution

30

Early Stage

71

Mid Stage

8

Late Stage

Phase Distribution114 total trials
Phase 1Safety & dosage
30(26.3%)
Phase 2Efficacy & side effects
71(62.3%)
Phase 3Large-scale testing
8(7.0%)
N/ANon-phased studies
5(4.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.6%

11 of 14 finished

Non-Completion Rate

21.4%

3 ended early

Currently Active

36

trials recruiting

Total Trials

116

all time

Status Distribution
Active(49)
Completed(11)
Terminated(3)
Other(53)

Detailed Status

unknown53
Recruiting31
Completed11
Not yet recruiting11
Active, not recruiting5
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
116
Active
36
Success Rate
78.6%
Most Advanced
Phase 3

Trials by Phase

Phase 130 (26.3%)
Phase 271 (62.3%)
Phase 38 (7.0%)
N/A5 (4.4%)

Trials by Status

recruiting3127%
active_not_recruiting54%
completed119%
not_yet_recruiting119%
terminated33%
unknown5346%
enrolling_by_invitation22%

Recent Activity

Clinical Trials (116)

Showing 20 of 116 trialsScroll for more
NCT07774377Phase 3

Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma

Not Yet Recruiting
NCT07754890Phase 1

Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma

Recruiting
NCT07746245Phase 2

The Efficacy of CAPCT in Patients With PTCL

Not Yet Recruiting
NCT06570447Phase 2

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Recruiting
NCT07397832Phase 2

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Recruiting
NCT05833724Phase 2

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Recruiting
NCT05270200Phase 1

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Recruiting
NCT07507318Phase 2

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Recruiting
NCT07234162Phase 3

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Recruiting
NCT07616336Phase 2

Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes

Not Yet Recruiting
NCT05586841Phase 1

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Completed
NCT07601607Phase 1

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Not Yet Recruiting
NCT07545967Phase 1

Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy

Recruiting
NCT07518602Phase 2

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

Recruiting
NCT07493148Phase 2

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Recruiting
NCT07493109Phase 3

Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP

Recruiting
NCT07320963Phase 1

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Not Yet Recruiting
NCT07380984Phase 2

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Recruiting
NCT07415980Phase 1

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Not Yet Recruiting
NCT06951997Phase 2

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
116